If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson trades at $825.38 and has moved in lockstep with the market. Its shares have returned 14.5% over the last six months ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

McKesson Corporation is a major pharmaceutical distributor that offers health care supply chain management, retail pharmacy, oncology, specialty care and health care information technology services.

(Reuters) - A $141 million settlement between McKesson Corp and a class of shareholders accusing the drug distributor of hiding the fact that it profited from a price-fixing conspiracy among generic ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson’s ...

In October, we joined forces with the Washington Post and reported a disturbing story of Washington at its worst - about an act of Congress that crippled the DEA's ability to fight the worst drug ...